中文 English

Singlera Genomics co-founder Kun Zhang speaks at Guangdong Precision Medicine Summit

December 31, 2016 – Guangzhou, China
The 2ndannual Guangdong Precision Medicine and Molecular Diagnostics Summit and the inaugural conference of the Precision Medicine and Molecular Diagnostics branch of the Guangdong Medical Association was held in Guangzhou, China. The Summit was organized by the Precision Medicine and Molecular Diagnostics branch of the Guangdong Medical Association with assistance from the First Affiliated Hospital of Zhongshan University. The purpose of the annual Summit is to share the latest updates on development, manufacturing, and clinical applications of precision medicine and to establish a platform for attendees to share their research and exchange clinical experiences.
The following experts in the field of precision medicine attended the Summit and presented special lectures: Tao Dai, Director of the Development Center for Medical Science and Technology, National Health and Family Planning Commission of the PRC, Haibo Wang, Director of the hospital quality monitoring system for the National Health and Family Planning Commission of the PRC, Hengjun Gao, Director of the National Engineering Center for Biochip, Zhibin Yao, President of the Guangdong Medical Association, Kun Zhang of the University of California San Diego (UCSD), Jun Yu of the Chinese University in Hong Kong, Guangmei Yan of Zhongshan University, Haipeng Xiao, Director of the First Affiliated Hospital of Zhongshan University, Ming Kuang and Zunfu Ke.
Kun Zhang, Professor in the Department of Bioengineering at UCSD and co-founder of Singlera Genomics, delivered the lecture “Application of DNA Methylation in Molecular Diagnosis”. He discussed how high-throughput sequencing techniques can detect not only gene mutations, insertions, deletions and copy number changes, but also methylation status; and in cancer, the level of DNA methylation varies based on the stage of cancer. Therefore, methylation detection can be applied to tumor stages and guide medication dosage and delivery. Methylation-based liquid biopsy has vast applications, including early cancer diagnosis, identifying primary tumor location and tracking cancer recurrence.
返 回